SpringerProtocols: Abstract: 21. Monoclonal Antibody-Based Strategies in Autoimmunity and Transplantation

21. Monoclonal Antibody-Based Strategies in Autoimmunity and Transplantation

By: Lucienne Chatenoud³

Abstract

Full Text

Download PDF (198K)

Monoclonal antibodies are homogeneous sets of immunoglobulins with well-defined specificity and biochemical characteristics. They were introduced into clinical practice in the early 1980s, and since then their use has rapidly expanded. Most of the side effects observed with first-generation murine (mouse or rat) antibodies have been successfully overcome with the advent of humanized (chimeric or CDR-grafted) and more recently fully human antibodies. Our aim is to review the major steps in the development of therapeutic monoclonal antibodies in the fields of transplantation and autoimmunity, and discuss the salient features of antibodies presently used in the clinic-notably anti-T-cell and anticytokine antibodies. The discussion will also focus on the unique capacity of some monoclonal antibodies to induce immune tolerance.

Affiliation(s): (3) Immunologie biologie-IRNEM-INSERM U580, Hôpital Necker Enfants Malades, Paris, France

Book Title: Adoptive Immunotherapy: Methods and Protocols

Series: Methods in Molecular Medicine | Volume: 109 | Pub. Date: Nov-30-2004 | Page Range: 297-328 | DOI: 10.1385/1-59259-862-5:297

Subject: Immunology

Key Words: Monoclonal antibody - immune tolerance - immunosuppression - autoimmune diseases - transplantation

References

Download References

1.	Fanslow, W. C., Sims, J. E., Sassenfeld, H., et al. (1990) Regulation of alloreactivity in vivo by a soluble form of the interleukin-1 receptor. Science 248, 739–742.

2.	Jacobs, C. A., Lynch, D. H., Roux, E. R., et al. (1991) Characterization and pharmacoki-netic parameters of recombinant soluble interleukin-4 receptor. Blood 77, 2396–2403.

3.	Ozmen, L., Gribaudo, G., Fountoulakis, M., Gentz, R., Landolfo, S., and Garotta, G. (1993) Mouse soluble IFN gamma receptor as IFN gamma inhibitor. Distribution, antigenicity, and activity after injection in mice. J. Immunol. 150, 2698–2705.

4.	Dinarello, C. A. (1991) Interleukin-1 and interleukin-1 antagonism. Blood 77, 1627–1652.

5.	Peppel, K., Crawford, D., and Beutler, B. (1991) A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity. J. Exp. Med. 174,1483–1489.

6.	Lesslauer, W., Tabuchi, H., Gentz, R., et al. (1991) Recombinant soluble tumor necrosis factor receptor proteins protect mice from lipopolysaccharide-induced lethality. Eur. J. Immunol. 21, 2883–2886.

7.	Feldmann, M. (2002) Development of anti-TNF therapy for rheumatoid arthritis. Nat. Rev. Immunol. 2, 364–371.

8.	Skoglund, C., Scheynius, A., Holmdahl, R., and Van Der Meide, P. H. (1988) Enhancement of DTH reaction and inhibition of the expression of class II transplantation antigens by in vivo treatment with antibodies against gamma-interferon. Clin. Exp. Immunol. 71,428–432.

9.	Nicoletti, F., Meroni, P. L., Landolfo, S., et al. (1990) Prevention of diabetes in BB/Wor rats treated with monoclonal antibodies to interferon-gamma. Lancet 336, 319.

10.	Bach, J. F. (1993) Strategies in immunotherapy of insulin-dependent diabetes mellitus. Ann. N. Y. Acad. Sci. 696, 364–376.

11.	Pujol-borrell, R., Todd, I., Doshi, M., et al. (1987) HLA class II induction in human islet cells by interferon-gamma plus tumour necrosis factor or lymphotoxin. Nature 326, 304–306.

12.	Sarvetnick, N., Liggitt, D., Pitts, S. L., Hansen, S. E., and Stewart, T. A. (1988) Insulin-dependent diabetes mellitus induced in transgenic mice by ectopic expression of class II MHC and interferon-gamma. Cell 52, 773–782.

13.	Hall, B. M., Bishop, G. A., Duggin, G. G., Horvath, J. S., Philips, J., and Tiller, D. J. (1984) Increased expression of HLA-DR antigens on renal tubular cells in renal trans-plants: relevance to the rejection response. Lancet 2, 247–251.

14.	Fuggle, S. V., Mcwhinnie, D. L., and Morris, P. J. (1987) Precise specificity of induced tubular HLA-class II antigens in renal allografts. Transplantation 44, 214–220.

15.	Greaves, M. F., Tursi, A., Playfair, J. H., Torrigiani, G., Zamir, R., and Roitt, I. M. (1969) Immunosuppressive potency and in vitro activity of antilymphocyte globulin. Lancet 1, 68–66.

16.	Martin, W. J. and Miller, J. F. (1968) Cell to cell interaction in the immune response. IV. Site of action of antilymphocyte globulin. J. Exp. Med. 128, 855–885.

17.	Bindon, C. I., Hale, G., and Waldmann, H. (1988) Importance of antigen specificity for complement-mediated lysis by monoclonal antibodies. Eur. J. Immunol. 18, 1507–1514.

18.	Isaacs, J. D., Clark, M. R., Greenwood, J., and Waldmann, H. (1992) Therapy with monoclonal antibodies. An in vivo model for the assessment of therapeutic potential. J. Immunol. 148,3062–3071.

19.	Abbs, I. C., Clark, M., Waldmann, H., Chatenoud, L., Koffman, C. G., and Sacks, S. H. (1994) Sparing of first dose effect of monovalent anti-CD3 antibody used in allograft rejection is associated with diminished release of pro-inflammatory cytokines. Therapeutic Immunology 1,325–331.

20.	Routledge, E. G., Lloyd, I., Gorman, S. D., Clark, M., and Waldmann, H. (1991) A humanized monovalent CD3 antibody which can activate homologous complement. Eur. J. Immunol. 21, 2717–2725.

21.	Wong, J. T. and Colvin, R. B. (1991) Selective reduction and proliferation of the CD4+ and CD8+T cell subsets with bispecific monoclonal antibodies: evidence for inter-T cell-mediated cytolysis. Clin. Immunol. Immunopathol. 58, 236–250.

22.	Wesselborg, S., Janssen, O., and Kabelitz, D. (1993) Induction of activation-driven death (apoptosis) in activated but not resting peripheral blood T cells. J. Immunol. 150,4338–4345.

23.	Kronke, M., Depper, J. M., Leonard, W. J., Vitetta, E. S., Waldmann, T. A., and Greene, W. C. (1985) Adult T cell leukemia: a potential target for ricin A chain immunotoxins. Blood 65, 1416–1421.

24.	Walz, G., Zanker, B., Brand, K., et al. (1989) Sequential effects of interleukin 2-diphthe-ria toxin fusion protein on T-cell activation. Proc. Natl. Acad. Sci. USA 86, 9485–9488.

25.	Moreland, L. W., Pratt, P. W., Bucy, R. P., Jackson, B. S., Feldman, J. W., and Koopman, W. J. (1994) Treatment of refractory rheumatoid arthritis with a chimeric anti-CD4 monoclonal antibody. Long-term followup of CD4+T cell counts. Arthritis Rheum. 37, 834–838.

26.	Qin, S., Cobbold, S. P., Pope, H., Elliott, J., Kioussis, D., Davies, J., and Waldmann, H. (1993) “Infectious” transplantation tolerance. Science 259, 974–977.

27.	Cobbold, S. P., Nolan, K. F., Graca, L., et al. (2003) Regulatory T cells and dendritic cells in transplantation tolerance: molecular markers and mechanisms. Immunol. Rev. 196,109–124.

28.	Waldmann, H. and Cobbold, S. (2001) Regulating the immune response to transplants. a role for CD4+regulatory cells? Immunity 14, 399–406.

29.	Bushell, A., Karim, M., Kingsley, C. I., and Wood, K. J. (2003) Pretransplant blood transfusion without additional immunotherapy generates CD25+CD4+regulatory T cells: a potential explanation for the blood-transfusion effect. Transplantation 76,449–455.

30.	Bushell, A., Morris, P. J., and Wood, K. J. (1995) Transplantation tolerance induced by antigen pretreatment and depleting anti-CD4 antibody depends on CD4+T cell regulation during the induction phase of the response. Eur. J. Immunol. 25, 2643–2649.

31.	Bank, I. and Chess, L. (1985) Perturbation of the T4 molecule transmits a negative signal to T cells. J. Exp. Med. 162, 1294–1303.

32.	Emmrich, F., Kanz, L., and Eichmann, K. (1987) Cross-linking of the T cell receptor complex with the subset-specific differentiation antigen stimulates interleukin 2 receptor expression in human CD4 and CD8 T cells. Eur. J. Immunol. 17, 529–534.

33.	Jabado, N., Le Deist, F., Fisher, A., and Hivroz, C. (1994) Interaction of HIV gp120 and anti-CD4 antibodies with the CD4 molecule on human CD4+T cells inhibits the binding activity of NF-AT, NF-kappa B and AP-1, three nuclear factors regulating interleukin-2 gene enhancer activity. Eur. J. Immunol. 24, 2646–2652.

34.	Jabado, N., Pallier, A., Jauliac, S., Fischer, A., and Hivroz, C. (1997) gp160 of HIV or anti-CD4 monoclonal antibody ligation of CD4 induces inhibition of JNK and ERK-2 activities in human peripheral CD4+T lymphocytes. Eur. J. Immunol. 27, 397–404.

35.	Jabado, N., Pallier, A., Le Deist, F., Bernard, F., Fischer, A., and Hivroz, C. (1997) CD4 ligands inhibit the formation of multifunctional transduction complexes involved in T cell activation. J. Immunol. 158, 94–103.

36.	Jauliac, S., Mazerolles, F., Jabado, N., et al. (1998) Ligands of CD4 inhibit the association of phospholipase Cgamma1 with phosphoinositide 3 kinase in T cells: regulation of this association by the phosphoinositide 3 kinase activity. Eur. J. Immunol. 28, 3183–3191.

37.	Chatenoud, L. and Bach, J. F. (1984) Antigenic modulation: a major mechanism of antibody action. Immunol. Today 5, 20–25.

38.	Hirsch, R., Eckhaus, M., Auchincloss, J. R., Sachs, D. H., and Bluestone, J. A. (1988) Effects of in vivo administration of anti-T3 monoclonal antibody on T cell function in mice. I. Immunosuppression of transplantation responses. J. Immunol. 140, 3766–3772.

39.	Chatenoud L.and Bach, J. F. (1982) The use of monoclonal antibodies for the follow-up of transplanted patients. Heart Transplant. 2, 47–51.

40.	Schwartz, R. H. (1990) A cell culture model for T lymphocyte clonal anergy. Science 248,1349–1356.

41.	Schwartz, R. H. (1996) Models of T cell anergy: is there a common molecular mechanism? [see comment] J. Exp. Med. 184, 1–8.

42.	Benjamin, R. J., Cobbold, S. P., Clark, M. R., and Waldmann, H. (1986) Tolerance to rat monoclonal antibodies. Implications for serotherapy. J. Exp. Med. 163, 1539–1552.

43.	Gutstein, N. L., Seaman, W. E., Scott, J. H., and Wofsy, D. (1986) Induction of immune tolerance by administration of monoclonal antibody to L3T4. J. Immunol. 137, 1127–1132.

44.	Cobbold, S. P., Adams, E., Marshall, S. E., Davies, J. D., and Waldmann, H. (1996) Mecha-nisms of peripheral tolerance and suppression induced by monoclonal antibodies to CD4 and CD8. Immunol. Rev. 149, 5–33.

45.	Cobbold, S. P., Adams, E., Graca, L., and Waldmann, H. (2003) Serial analysis of gene expression provides new insights into regulatory T cells. Semin. Immunol. 15, 209–214.

46.	Chatenoud, L. (2003) CD3-specific antibody-induced active tolerance: from bench to bed-side. Nat. Rev. Immunol. 3, 123–132.

47.	Chatenoud, L., Thervet, E., Primo, J., and Bach, J. F. (1994) Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc. Natl. Acad. Sci. USA 91, 123–127.

48.	Nicolls, M. R., Aversa, G. G., Pearce, N. W., et al. (1993) Induction of long-term specific tolerance to allografts in rats by therapy with an anti-CD3-like monoclonal antibody. Transplantation 55, 459–468.

49.	Pearson, T. C., Madsen, J. C., Larsen, C. P., Morris, P. J., and Wood, K. J. (1992) Induc-tion of transplantation tolerance in adults using donor antigen and anti-CD4 monoclonal antibody. Transplantation 54, 475–483.

50.	Thomas, F. T., Ricordi, C., Contreras, J. L., et al. (1999) Reversal of naturally occuring diabetes in primates by unmodified islet xenografts without chronic immunosuppression. Transplantation 67, 846–854.

51.	Thomas, J. M., Neville, D. M., Contreras, J. L., et al. (1997) Preclinical studies of allograft tolerance in rhesus monkeys: a novel anti-CD3-immunotoxin given peritransplant with donor bone marrow induces operational tolerance to kidney allografts. Transplantation 64, 124–135.

52.	Niimi, M., Pearson, T. C., Larsen, C. P., et al. (1998) The role of the CD40 pathway in alloantigen-induced hyporesponsiveness in vivo. J. Immunol. 161, 5331–5337.

53.	Larsen, C. P., Elwood, E. T., Alexander, D. Z., et al. (1996) Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 381, 434–438.

54.	Kirk, A. D., Burkly, L. C., Batty, D. S., et al. (1999) reatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates [see comments]. Nat. Med. 5, 686–693.

55.	Bushell, A., Niimi, M., Morris, P. J., and Wood, K. J. (1999) Evidence for immune regulation in the induction of transplantation tolerance: a conditional but limited role for IL-4. J. Immunol. 162, 1359–1366.

56.	Plain, K. M., Chen, J., Merten, S., He, X. Y., and Hall, B. M. (1999) Induction of specific tolerance to allografts in rats by therapy with non-mitogenic, non-depleting anti-CD3 monoclonal antibody: association with TH2 cytokines not anergy. Transplantation 67, 605–613.

57.	Wood, K. J., Luo, S., and Akl, A. (2004) Regulatory T cells: potential in organ transplantation. Transplantation 77, S6–8.

58.	Karim, M., Kingsley, C. I., Bushell, A. R., Sawitzki, B. S., and Wood, K. J. (2004) Alloan-tigen-induced CD25+CD4+regulatory T cells can develop in vivo from CD25-CD4+precursors in a thymus-independent process. J. Immunol. 172, 923–928.

59.	Graca, L., Le Moine, A., Cobbold, S. P., and Waldmann, H. (2003) Antibody-induced transplantation tolerance: the role of dominant regulation. Immunol. Res. 28, 181–191.

60.	Graca, L., Thompson, S., Lin, C. Y., Adams, E., Cobbold, S. P., and Waldmann, H. (2002) Both CD4(+)CD25(+) and CD4(+)CD25(-) regulatory cells mediate dominant transplan-tation tolerance. J. Immunol. 168, 5558–5565.

61.	Chatenoud, L., Salomon, B., and Bluestone, J. A. (2001) Suppressor T cells-they’re back and critical for regulation of autoimmunity! Immunol. Rev. 182, 149–163.

62.	Bach, J. F. and Chatenoud, L. (2001) Tolerance to islet autoantigens and type I diabetes. Annu. Rev. Immunol. 19, 131–161.

63.	Hall, B. M., Pearce, N. W., Gurley, K. E., and Dorsch, S. E. (1990) Specific unresponsive-ness in rats with prolonged cardiac allograft survival after treatment with cyclosporine. III. Further characterization of the CD4+suppressor cell and its mechanisms of action. J. Exp. Med. 171, 141–157.

64.	Belghith, M., Bluestone, J. A., Barriot, S., Megret, J., Bach, J. F., and Chatenoud, L. (2003) TGF-β dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nature Medicine 9, 1202–1208.

65.	Zelenika, D., Adams, E., Humm, S., et al. (2002) Regulatory T cells overexpress a subset of Th2 gene transcripts. J. Immunol. 168, 1069–1079.

66.	Chatenoud, L., Baudrihaye, M. F., Chkoff, N., Kreis, H., Goldstein, G., and Bach, J. F. (1986) Restriction of the human in vivo immune response against the mouse monoclonal antibody OKT3. J. Immunol. 137, 830–838.

67.	Chatenoud, L. (1986) The immune response against therapeutic monoclonal antibodies. Immunol. Today 7, 367–368.

68.	Chatenoud, L., Jonker, M., Villemain, F., Goldstein, G., and Bach, J.F. (1986) The human immune response to the OKT3 monoclonal antibody is oligoclonal. Science 232,1406–1408.

69.	Baudrihaye, M. F., Chatenoud, L., Kreis, H., Goldstein, G., and Bach, J. F. (1984) Unusually restricted anti-isotype human immune response to OKT3 monoclonal antibody. Eur. J. Immunol. 14,686–691.

70.	Abramowicz, D., Crusiaux, A., and Goldman, M. (1992) Anaphylactic shock after retreatment with OKT3 monoclonal antibody. N. Engl. J. Med. 327, 736.

71.	Abramowicz, D., Crusiaux, A., Niaudet, P., Kreis, H., Chatenoud, L., and Goldman, M. (1996) The IgE humoral response in OKT3-treated patients-Incidence and fine specificity. Transplantation 61, 577–581.

72.	Hricik, D. E., Mayes, J. T., and Schulak, J. A. (1990) Inhibition of anti-OKT3 antibody generation by cyclosporine-results of a prospective randomized trial. Transplantation 50, 237–240.

73.	Riechmann, L., Clark, M., Waldmann, H., and Winter, G. (1988) Reshaping human antibodies for therapy. Nature 332, 323–327.

74.	Bolt, S., Routledge, E., Lloyd, I., et al. (1993) The generation of a humanized, non-mito-genic CD3 monoclonal antibody which retains in vitro immunosuppressive properties. Eur. J. Immunol. 23, 403–411.

75.	Alegre, M.L., Peterson, L.J., Xu, D., et al. (1994) A non-activating “humanized” anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo. Transplantation 57, 1537–1543.

76.	Elliott, M. J., Maini, R. N., Feldmann, M., et al. (1994) Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet 344, 1125–1127.

77.	Nashan, B., Moore, R., Amlot, P., Schmidt, A. G., Abeywickrama, K., and Soulillou, J. P. (1997) Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group [published erratum appears in Lancet 1997 350 (9089), 1484]. Lancet 350, 1193–1198.

78.	Vincenti, F., Kirkman, R., Light, S., et al. (1998) Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group [see comments]. N. Engl. J. Med. 338, 161–165.

79.	Chatenoud, L., Ferran, C., Legendre, C., et al. (1990) In vivo cell activation following OKT3 administration. Systemic cytokine release and modulation by corticosteroids. Transplantation 49, 697–702.

80.	Abramowicz, D., Schandene, L., Goldman, M., et al. (1989) Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation 47, 606–608.

81.	Marks, J. D., Hoogenboom, H. R., Bonnert, T. P., Mccafferty, J., Griffiths, A. D., and Winter, G. (1991) By-passing immunization. Human antibodies fromV-gene libraries displayed on phage. J. Mol. Biol. 222, 581–597.

82.	Lubin, I., Segall, H., Marcus, H., et al. (1994) Engraftment of human peripheral blood lymphocytes in normal strains of mice. Blood 83, 2368–2381.

83.	Calne, R., Moffatt, S. D., Friend, P. J.,et al.(1999) Campath IH allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients. Transplantation 68, 1613–1616.

84.	Mathieson, P. W., Cobbold, S.P., Hale, G., et al. (1990) Monoclonal-antibody therapy in systemic vasculitis. N. Engl. J. Med. 323, 250–254.

85.	Lockwood, C. M., Thiru, S., Isaacs, J. D., Hale, G., and Waldmann, H. (1993) Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy. Lancet 341, 1620–1622.

86.	Lockwood, C. M., Thiru, S., Stewart, S., et al. (1996) reatment of refractory Wegener’s granulomatosis with humanized monoclonal antibodies [see comments]. QJM 89,903–912.

87.	Billingham, R. E., Brent, L., and Medawar, P. B. (1953) Actively acquired tolerance to foreign cells. Nature 172, 603–606.

88.	Roser, B. J. (1989) Cellular mechanisms in neonatal and adult tolerance. Immunol. Rev. 107,179–202.

89.	Donckier, V., Flamand, V., Desalle, F., et al. (1998) IL-12 prevents neonatal induction of transplantation tolerance in mice. Eur. J. Immunol. 28, 1426–1430.

90.	Donckier, V., Wissing, M., Bruyns, C., et al. (1995) Critical role of interleukin 4 in the induction of neonatal transplantation tolerance. Transplantation 59, 1571–1576.

91.	Monaco, A. P., Wood, M. L., and Russell, P. S. (1966) Studies on heterologous antilym-phocyte serum in mice. III. Immunological tolerance and chimerism produced across the H2-locus with adult thymectomy and antilymphocyte serum. Ann. N. Y. Acad. Sci. 129, 190–209.

92.	Wood, M. L., Monaco, A. P., Gozzo, J. J., and Liegeois, A. (1971) Use of homozygous allogeneic bone marrow for induction of tolerance with antilymphocyte serum: dose and timing. Transplant. Proc. 3, 676–679.

93.	Thomas, F. T., Carver, F. M., Foil, M. B., et al. (1983) Long-term incompatible kidney survival in outbred higher primates without chronic immunosuppression. Ann. Surg. 198, 370–378.

94.	Thomas, J. M., Carver, F. M., Foil, M. B., Hall, W. R., Adams, C., and Fahrenbruch, G. B. (1983) Renal allograft tolerance induced with ATG and donor bone marrow in outbred rhesus monkeys. Transplantation 36, 104–106.

95.	Thomas, J., Alqaisi, M., Cunningham, P., et al. (1992) The development of a posttransplant TLI treatment strategy that promotes organ allograft acceptance without chronic immunosuppression. Transplantation 53, 247–258.

96.	Hamawy, M. M. and Knechtle, S. J. (1998) Strategies for tolerance induction in nonhuman primates. Curr. Opin. Immunol. 10, 513–517.

97.	Qin, S. X., Wise, M., Cobbold, S. P., et al. (1990) Induction of tolerance in peripheral T cells with monoclonal antibodies. Eur. J. Immunol. 20, 2737–2745.

98.	Gershon, R. K. and Kondo, K. (1971) Infectious immunological tolerance. Immunology 21,903–914.

99.	Cobbold, S. and Waldmann, H. (1998) Infectious tolerance. Curr. Opin. Immunol. 10, 518–524.

100.	Davies, J. D., Leong, L. Y., Mellor, A., Cobbold, S. P., and Waldmann, H. (1996) T cell suppression in transplantation tolerance through linked recognition. J. Immunol. 156, 3602–3607.

101.	Isobe, M., Yagita, H., Okumura, K., and Ihara, A. (1992) Specific acceptance of cardiac allograft after treatment with antibodies to ICAM-1 and LFA-1. Science 255, 1125–1127.

102.	Larsen, C. P. and Pearson, T. C. (1997) The CD40 pathway in allograft rejection, acceptance, and tolerance. Curr. Opin. Immunol. 9, 641–647.

103.	Mosmann, T. R. and Coffman, R. L. (1989) TH1 and TH2 cells: different patterns of lym-phokine secretion lead to different functional properties. Annu. Rev. Immunol. 7,145–173.

104.	Nickerson, P., Steurer, W., Steiger, J., Zheng, X., Steele, A. W., and Strom, T. B. (1994) Cytokines and the Th1/Th2 paradigm in transplantation. Curr. Opin. Immunol. 6, 757–764.

105.	Bendelac, A., Carnaud, C., Boitard, C., and Bach, J. F. (1987) Syngeneic transfer of autoimmune diabetes from diabetic NOD mice to healthy neonates. Requirement for both L3T4+and Lyt-2+T cells. J. Exp. Med. 166, 823–832.

106.	Wicker, L. S., Miller, B. J., and Mullen, Y. (1986) Transfer of autoimmune diabetes mel-litus with splenocytes from nonobese diabetic (NOD) mice. Diabetes 35, 855–860.

107.	Yagi, H., Matsumoto, M., Kunimoto, K., Kawaguchi, J., Makino, S., and Harada, M. (1992) Analysis of the roles of CD4+and CD8+T cells in autoimmune diabetes of NOD mice using transfer to NOD athymic nude mice. Eur. J. Immunol. 22, 2387–2393.

108.	Haskins, K., Portas, M., Bergman, B., Lafferty, K., and Bradley, B. (1989) Pancreatic islet-specific T-cell clones from nonobese diabetic mice. Proc. Natl. Acad. Sci. USA 86, 8000–8004.

109.	Katz, J. D., Benoist, C., and Mathis, D. (1995) T helper cell subsets in insulin-dependent diabetes. Science 268, 1185–1188.

110.	Healey, D., Ozegbe, P., Arden, S., Chandler, P., Hutton, J., and Cooke, A. (1995) In vivo activity and in vitro specificity of CD4+Th1 and Th2 cells derived from the spleens of diabetic NOD mice. J. Clin. Invest. 95, 2979–2985.

111.	Herbelin, A., Gombert, J. M., Lepault, F., Bach, J. F., and Chatenoud, L. (1998) Mature mainstream TCR alphabeta(+)CD4(+) thymocytes expressing L-selectin mediate’ ^’active tolerance’’ in the nonobese diabetic mouse. J. Immunol. 161, 2620–2628.

112.	Lepault, F. and Gagnerault, M. C. (2000) Characterization of peripheral regulatory CD4(+) T cells that prevent diabetes onset in nonobese diabetic mice. J. Immunol. 164, 240–247.

113.	Lepault, F., Gagnerault, M. C., Faveeuw, C., Bazin, H., and Boitard, C. (1995) Lack of L-selectin expression by cells transferring diabetes in NOD mice: insights into the mechanisms involved in diabetes prevention by Mel-14 antibody treatment. Eur. J. Immunol. 25, 1502–1507.

114.	Chatenoud, L., Primo, J., and Bach, J. F. (1997) CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. J. Immunol. 158, 2947–2954.

115.	Alegre, M. L., Collins, A. M., Pulito, V. L., et al. (1992) Effect of a single amino acid mutation on the activating and immunosuppressive properties of a “humanized” OKT3 monoclonal antibody. J. Immunol. 148, 3461–3468.

116.	Herold, K. C., Hagopian, W., Auger, J. A., et al. (2002) Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N. Engl. J. Med. 346, 1692–1698.

117.	Cosimi, A. B., Burton, R. C., Colvin, R. B., et al. (1981) Treatment of acute renal allograft rejection with OKT3 monoclonal antibody. Transplantation 32, 535–539.

118.	Cosimi, A. B., Colvin, R. B., Burton, R. C., et al. (1981) Use of monoclonal antibodies to T-cell subsets for immunologic monitoring and treatment in recipients of renal allografts. N. Engl. J. Med. 305, 308–314.

119.	Ortho Multicenter Transplant Study Group (1985) A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N. Engl. J. Med. 313, 337–342.

120.	Goldstein, G., Kremer, A. B., Barnes, L., and Hirsch, R. L. (1987) OKT3 monoclonal antibody reversal of renal and hepatic rejection in pediatric patients. J. Pediatr. 111, 1046–1050.

121.	Hricik, D. E., Zarconi, J., and Schulak, J. A. (1989) Influence of low-dose cyclosporine on the outcome of treatment with OKT3 for acute renal allograft rejection. Transplantation 47, 272–277.

122.	Norman, D. J., Barry, J. M., Bennett, W. M., et al. (1988) The use of OKT3 in cadaveric renal transplantation for rejection that is unresponsive to conventional anti-rejection therapy. Am. J. Kidney Dis. 11, 90–93.

123.	Colonna Jo, D., Goldstein, L. I., Brems, J. J., et al. (1987) A prospective study on the use of monoclonal anti-T3-cell antibody (OKT3) to treat steroid-resistant liver transplant rejection. Arch. Surg. 122, 1120–1123.

124.	Woodle, E. S., Thistlethwaite Jr., J. R., Emond, J. C., et al. (1991) OKT3 therapy for hepatic allograft rejection. Differential response in adults and children. Transplantation 51, 1207–1212.

125.	Gilbert, E. M., Dewitt, C. W., Eiswirth, C. C., et al. (1987) Treatment of refractory cardiac allograft rejection with OKT3 monoclonal antibody. Am. J. Med. 82, 202–206.

126.	Frey, D. J., Matas, A. J., Gillingham, K. J., et al. (1992) Sequential therapy-a prospective randomized trial of MALG versus OKT3 for prophylactic immunosuppression in cadaver renal allograft recipients. Transplantation 54, 50–56.

127.	Debure, A., Chkoff, N., Chatenoud, L., et al. (1988) One-month prophylactic use of OKT3 in cadaver kidney transplant recipients. Transplantation 45, 546–553.

128.	Abramowicz, D., Goldman, M., De Pauw, L., Vanherweghem, J. L., Kinnaert, P., and Vereerstraeten, P. (1992) The long-term effects of prophylactic OKT3 monoclonal antibody in cadaver kidney transplantation-a single-center, prospective, randomized study. Transplantation 54, 433–437.

129.	Opelz, G. (1995) Efficacy of rejection prophylaxis with OKT3 in renal transplantation. Collaborative Transplant Study. Transplantation 60, 1220–1224.

130.	Farges, O., Ericzon, B. G., Bresson-hadni, S., et al. (1994) A randomized trial of OKT3-based versus cyclosporine-based immunoprophylaxis after liver transplantation. Long-term results of a European and Australian multicenter study. Transplantation 58,891–898.

131.	Millis, J. M., Mcdiarmid, S. V., Hiatt, J. R., et al. (1989) Randomized prospective trial of OKT3 for early prophylaxis of rejection after liver transplantation. Transplantation 47, 82–88.

132.	Eason, J. D. and Cosimi, A. B. (1999) Biologic immunosuppressive agents. In: Transplan tation. Ginns, L., Cosimi, A., and Morris, P., eds. Blackwell Science, Malden, MA, pp. 196–224.

133.	Robbins, R. C., Oyer, P. E., Stinson, E. B., and Starnes, V. A. (1992) The use of monoclonal antibodies after heart transplantation. Transplant. Sci. 2, 22–27.

134.	Chatenoud, L., Ferran, C., Reuter, A., et al. (1989) Systemic reaction to the anti-T-cell monoclonal antibody OKT3 in relation to serum levels of tumor necrosis factor and inter-feron-gamma. N. Engl. J. Med. 320, 1420–1421.

135.	Cosimi, A. B. (1987) Clinical development of Orthoclone OKT3. Transplant. Proc. 19, 7–16.

136.	Friend, P. J., Hale, G., Chatenoud, L., et al. (1999) Phase I study of an engineered aglycosylated humanized CD3 antibody in renal transplant rejection. Transplantation 68, 1632–1637.

137.	Woodle, E. S., Xu, D., Zivin, R. A., et al. (1999) Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma1(Ala-Ala) in the treatment of acute renal allograft rejection. Transplantation 68, 608–616.

138.	Le Mauff, B., Hourmant, M., Rougier, J. P., et al. (1991) Effect of anti-LFA1 (CD11a) monoclonal antibodies in acute rejection in human kidney transplantation. Transplantation 52, 291–296.

139.	Maraninchi, D., Mawas, C., Stoppa, A. M., et al. (1989) Anti LFA1 monoclonal antibody for the prevention of graft rejection after T cell-depleted HLA-matched bone marrow transplantation for leukemia in adults. Bone Marrow Transplant. 4, 147–150.

140.	Soulillou, J. P., Cantarovich, D., Le Mauff, B., et al. (1990) Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts. N. Engl. J. Med. 322, 1175–1182.

141.	Kriaa, F., Hiesse, C., Alard, P., et al. (1993) Prophylactic use of the anti-IL-2 receptor monoclonal antibody LO-Tact-1 in cadaveric renal transplantation: results of a randomized study. Transplant. Proc. 25, 817–819.

142.	Kirkman, R. L., Shapiro, M. E., Carpenter, C. B., et al. (1991) A randomized prospective trial of anti-Tac monoclonal antibody in human renal transplantation. Transplantation 51, 107–113.

143.	Waldmann, T. A. and O’Shea, J. (1998). The use of antibodies against the IL-2 receptor in transplantation. Curr. Opin. Immunol. 10, 507–512.

144.	Bumgardner, G. L., Hardie, I., Johnson, R. W., et al. (2001) Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation. Transplantation 72, 839–845.

145.	Adu, D., Cockwell, P., Ives, N. J., Shaw, J., and Wheatley, K. (2003) Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomised trials. BMJ 326, 789.

146.	Nussenblatt, R. B. (2002) Bench to bedside: new approaches to the immunotherapy of uveitic disease. Int. Rev. Immunol. 21, 273–289.

147.	Guex-Crosier, Y., Raber, J., Chan, C. C., et al. (1997) Humanized antibodies against the alpha-chain of the IL-2 receptor and against the beta-chain shared by the IL-2 and IL-15 receptors in a monkey uveitis model of autoimmune diseases. J. Immunol. 158, 452–458.

148.	Shizuru, J. A., Taylor-Edwards, C., Banks, B. A., Gregory, A. K., and Fathman, C. G. (1988) Immunotherapy of the nonobese diabetic mouse: treatment with an antibody to T-helper lymphocytes. Science 240, 659–662.

149.	Wofsy, D. and Seaman, W. E. (1987) Reversal of advanced murine lupus in NZB/NZW F1 mice by treatment with monoclonal antibody to L3T4. J. Immunol. 138, 3247–3253.

150.	Horneff, G., Burmester, G. R., Emmrich, F., and Kalden, J. R. (1991) Treatment of rheumatoid arthritis with an anti-CD4 monoclonal antibody. Arthritis Rheum. 34, 129–140.

151.	Wendling, D., Wijdenes, J., Racadot, E., and Morel-Fourrier, B. (1991) Therapeutic use of monoclonal anti-CD4 antibody in rheumatoid arthritis. J. Rheumatol. 18, 325–327.

152.	Morel, P., Revillard, J. P., Nicolas, J. F., Wijdenes, J., Rizova, H., and Thivolet, J. (1992) Anti-CD4 monoclonal antibody therapy in severe psoriasis. J. Autoimmun. 5, 465–477.

153.	Emmrich, J., Seyfarth, M., Fleig, W. E., and Emmrich, F. (1991) Treatment of inflammatory bowel disease with anti-CD4 monoclonal antibody. Lancet 338, 570–571.

154.	Reiter, C., Kakavand, B., Rieber, E. P., Schattenkirchner, M., Riethmuller, G., and Kruger, K. (1991) Treatment of rheumatoid arthritis with monoclonal CD4 antibody M-T151. Clinical results and immunopharmacologic effects in an open study, including repeated administration. Arthritis Rheum. 34, 525–536.

155.	Goldberg, D., Chatenoud, L., Morel, P., et al. (1990) Preliminary trial of an anti-CD4 monoclonal antibody (MoAb) in rheumatoid arthritis (RA). Arthritis Rheum. 33, S153.

156.	Goldberg, D., Morel, P., Chatenoud, L., et al. (1991) Immunological effects of high dose administration of anti-CD4 antibody in rheumatoid arthritis patients. J. Autoimmun. 4, 617–630.

157.	Bachelez, H., Flageul, B., Dubertret, L., et al. (1998) Treatment of recalcitrant plaque psoriasis with a humanized non-depleting antibody to CD4. J. Autoimmun. 11, 53–62.

158.	Moreland, L. W., Bucy, R. P., Tilden, A., et al. (1993) Use of a chimeric monoclonal anti-CD4 antibody in patients with refractory rheumatoid arthritis. Arthritis Rheum. 36, 307–318.

159.	Van Der Lubbe, P. A., Dijkmans, B. A., Markusse, H. M., Nassander, U., and Breedveld, F. C. (1995) A randomized, double-blind, placebo-controlled study of CD4 monoclonal antibody therapy in early rheumatoid arthritis. Arthritis Rheum. 38, 1097–1106.

160.	Van Der Lubbe, P. A., Reiter, C., Breedveld, F. C., et al. (1993) Chimeric CD4 mono-clonal antibody cM-T412 as a therapeutic approach to rheumatoid arthritis. Arthritis Rheum. 36, 1375–1379.

161.	Van Der Lubbe, P. A., Reiter, C., Miltenburg, A. M., et al. (1994) Treatment of rheumatoid arthritis with a chimeric CD4 monoclonal antibody (cM-T412): immunopharmacological aspects and mechanisms of action. Scand. J. Immunol. 39, 286–294.

162.	Choy, E. H., Adjaye, J., Forrest, L., Kingsley, G. H., and Panayi, G. S. (1993) Chimaeric anti-CD4 monoclonal antibody cross-linked by monocyte Fc gamma receptor mediates apoptosis of human CD4 lymphocytes. Eur. J. Immunol. 23, 2676–2681.

163.	van Oosten, B. W., Lai, M., Hodgkinson, S., et al. (1997) Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial. Neurology 49, 351–357.

164.	Gottlieb, A. B., Lebwohl, M., Shirin, S., et al. (2000) Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: results of a pilot, multicenter, multiple-dose, placebo-controlled study. J. Am. Acad. Dermatol. 43, 595–604.

165.	Brennan, F. M. and Feldmann, M. (1992) Cytokines in autoimmunity. Curr. Opin. Immunol. 4, 754–759.

166.	Williams, R. O., Mason, L. J., Feldmann, M., and Maini, R. N. (1994) Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis. Proc. Natl. Acad. Sci. USA 91, 2762–2766.

167.	Elliott, M. J., Maini, R. N., Feldmann, M., et al. (1994) Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344, 1105–1110.

168.	Maini, R. N., Breedveld, F. C., Kalden, J. R., et al. (1998) herapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis [see comments]. Arthritis Rheum. 41, 1552–1563.

169.	Feldmann, M. and Maini, T. (2001) Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu. Rev. Immunol. 19, 163–196.

170.	Maini, R., St Clair, E. W., Breedveld, F., et al. (1999) Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354, 1932–1939.

171.	Lipsky, P. E., van der Heijde, D. M., St Clair, E. W., et al. (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N. Engl. J. Med. 343, 1594–1602.

172.	Rankin, E. C., Choy, E. H., Kassimos, D., et al. (1995) The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br. J. Rheumatol. 34, 334–342.

173.	Furst, D. E., Weisman, M., Paulus, H. E., et al. (2003) Intravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein, Ro 45-2081 (lenercept): results of a dose-finding study in rheumatoid arthritis. J. Rheumatol. 30, 2123–2126.

174.	Moreland, L. W., Baumgartner, S. W., Schiff, M. H., et al. (1997) reatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein [see comments]. N. Engl. J. Med. 337, 141–147.

175.	Moreland, L. W., Margolies, G., Heck, Jr., L. W., et al. (1996) Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: toxicity and dose finding trial in refractory rheumatoid arthritis. J. Rheumatol. 23, 1849–1855.

176.	Kempeni, J. (1999) Preliminary results of early clinical trials with the fully human anti-TNFalpha monoclonal antibody D2E7. Ann. Rheum. Dis. 58(Suppl 1), I70–72.

177.	den Broeder, A., van de Putte, L., Rau, R., et al. (2002) A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis. J. Rheumatol. 29, 2288–2298.

178.	Van Dullemen, H. M., Van Deventer, S. J., Hommes, D. W., et al. (1995) Treatment of Crohn’s disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 109, 129–135.

179.	Ghosh, S., Goldin, E., Gordon, F. H., et al. (2003) Natalizumab for active Crohn’s disease. N. Engl. J. Med. 348, 24–32.

180.	Van Deventer, S. J. (1997) Tumour necrosis factor and Crohn’s disease Gut 40, 443–448.

181.	Plevy, S. E., Landers, C. J., Prehn, J., et al. (1997) A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn’s disease. J. Immunol. 159, 6276–6282.

182.	Lovell, D. J., Giannini, E. H., Reiff, A., et al. (2000) Etanercept in children with pol-yarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N. Engl. J. Med. 342, 763–769.

183.	Brandt, J., Haibel, H., Cornely, D., et al. (2000) Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum. 43, 1346–1352.

184.	Mease, P. J., Goffe, B. S., Metz, J., VanderStoep, A., Finck, B., and Burge, D. J. (2000) Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 356, 385–390.

185.	Chaudhari, U., Romano, P., Mulcahy, L. D., Dooley, L. T., Baker, D. G., and Gottlieb, A. B. (2001) Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 357, 1842–1847.

186.	Gomez-Reino, J. J., Carmona, L., Valverde, V. R., Mola, E. M., and Montero, M. D. (2003) Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum. 48, 2122–2127.

187.	Isaacs, J. D., Watts, R. A., Hazleman, B. L., et al. (1992) Humanised monoclonal antibody therapy for rheumatoid arthritis. Lancet 340, 748–752.

188.	Moreau, T., Thorpe, J., Miller, D., et al. (1994) Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis [published erratum appears in Lancet 1994 344(8920), 486]. Lancet 344, 298-301.

189.	Coles, A. J., Wing, M. G., Molyneux, P., et al. (1999) Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann. Neurol. 46, 296–304.

190.	Coles, A. J., Wing, M. G., Smith, S., et al. (1999) Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet 354, 1691–1695.

191.	Knechtle, S. J., Pirsch, J. D., Fechner, J. H., et al. (2003) Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. Am. J. Transplant. 3, 722–730.

192.	Kirk, A. D., Hale, D. A., Mannon, R. B., et al. (2003) Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation 76, 120–129.

193.	Miller, D. H., Khan, O. A., Sheremata, W. A., et al. (2003) A controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 348, 15–23.

194.	Lebwohl, M., Christophers, E., Langley, R., Ortonne, J. P., Roberts, J., and Griffiths, C. E. (2003) An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch. Dermatol. 139, 719–727.

195.	Krueger, G. G. (2003) Clinical response to alefacept: results of a phase 3 study of intravenous administration of alefacept in patients with chronic plaque psoriasis. J. Eur. Acad. Dermatol. Venereol. 17 Suppl 2, 17–24.

196.	Rastetter, W., Molina, A., and White, C. A. (2004) Rituximab: expanding role in therapy for lymphomas and autoimmune diseases. Annu. Rev. Med. 55, 477–503.

197.	Shaw, T., Quan, J., and Totoritis, M. C. (2003) B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience. Ann. Rheum. Dis. 62(Suppl 2), 55–59.

198.	Silverman, G. J. and Weisman, S. (2003) Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. Arthritis Rheum. 48, 1484–1492.

199.	Leandro, M. J., Edwards, J. C., and Cambridge, G. (2002) Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann. Rheum. Dis. 61, 883–888.

200.	De Vita, S., Zaja, F., Sacco, S., De Candia, A., Fanin, R., and Ferraccioli, G. (2002) Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells. Arthritis Rheum. 46, 2029–2033.

Comments (Loading...)

Post comment/View all comments